Michael Houghton,Abdolamir Landi,Michael Logan,John L. Law,Darren Hockman,Chao Chen
申请号：
US16334683
公开号：
US20190209677A1
申请日:
2017.09.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides； b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2； and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2； and b) a pharmaceutically acceptable excipient.
